focus -WSS

focus

author：explore 2025-09-03 15:19:03 - browse：4

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： When waiting feels immoral: Empathy in the emergency department

WSS

Late stage cancers on the rise after pandemic delayed screenings

Restaurant meals are packed with calories, and we still keep eating them

Doctors push to include dialysis machines in emergency stockpile

Study links childhood stress with decline in older age

Pennsylvania man bitten on the head by bear during attack in his garage

CDC recommends RSV monoclonal antibody for infants

Wikipedia

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Moonlake's readout produced a cash windfall. Risks remain

It costs an awful lot of money to give away a kidney

Medical leaders decry Supreme Court decision on affirmative action

NFL doctors' conflicts of interest could endanger players, report says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

2 officers injured in shooting in Orlando, police say

The cancer drug shortage isn’t new — and neither are the solutions

FDA approves Sage Therapeutics’ rapid

Wikipedia

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Pharma showers House GOP doctor with campaign cash

Election results set back Medicaid expansion plans

It costs an awful lot of money to give away a kidney

With heat waves through August, officials warn of health risks

CDC recommends RSV monoclonal antibody for infants

hotspot

focus

hotspot

knowledge